CD19-CAR-T Cells Bearing a KIR/PD-1-Based Inhibitory CAR Eradicate CD19(+)HLA-C1(−) Malignant B Cells While Sparing CD19(+)HLA-C1(+) Healthy B Cells

SIMPLE SUMMARY: CD19-targeted chimeric antigen receptor (CAR) T (CD19-CAR-T) cell therapy usually causes B cell aplasia because of “on-target off-tumor” toxicity. The aim of the study was to assess the concept that the introduction of an inhibitory CAR (iCAR) into CAR-T cells could alleviate the sid...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Lei, Farooq, Muhammad Asad, Gao, Yaoxin, Zhang, Li, Niu, Congyi, Ajmal, Iqra, Zhou, Ying, He, Cong, Zhao, Guixia, Yao, Jie, Liu, Mingyao, Jiang, Wenzheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564565/
https://www.ncbi.nlm.nih.gov/pubmed/32933182
http://dx.doi.org/10.3390/cancers12092612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564565/
https://www.ncbi.nlm.nih.gov/pubmed/32933182
http://dx.doi.org/10.3390/cancers12092612

Ejemplares similares